Results from the phase III 006 Study of Cytalux (pafolacianine) injection for intraoperative imaging of folate receptor positive ovarian cancer reports that use of Cytalux during ovarian cancer surgery demonstrated identification of additional lesions that were not identified with conventional means and not otherwise planned for resection.
Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.
